For Immediate Release
Chicago, IL –July 26, 2017 – Today, Zacks Equity Research discusses the Industry: Chemicals, Part 2, including Dow Chemical (NYSE: DOW – Free Report), DuPont (NYSE:DD – Free Report), Syngenta (NYSE: SYT – Free Report), Albemarle Corp.’s (NYSE: ALB – Free Report) and Monsanto Company (NYSE: MON – Free Report).
Industry: Chemicals, Part 2
The chemical industry is back in business after being stuck in limbo for a spell, making it an attractive investment proposition. The industry’s upturn is expected to continue this year on continued momentum across major end-markets.
Despite a few industry-related headwinds -- weak demand across agricultural and energy markets and sluggishness in China -- there are a number of reasons to be optimistic about the broader chemical industry for both the short and long haul. Let’s find out what’s supporting the bullish case for chemical stocks.
Shale Bounty – Driving Force for Chemical Spending
The shale gas revolution in the U.S. has been a huge driving force behind chemical investment on plants and equipment in the country. According to the American Chemistry Council (“ACC”), the U.S. has emerged as an attractive investment location and petrochemical makers are now significantly expanding capacity in the country, leveraging new supplies of natural gas. New methods of extraction such as horizontal drilling and hydraulic fracturing (or fracking) are boosting shale production, bringing down prices of ethane (derived from shale gas) in the process.
The shale boom has incentivized a number of chemical companies to pump in billions of dollars for setting up facilities (crackers) in the U.S. to produce ethylene and propylene in a cost-effective way. Per the ACC, 310 new chemical projects have been already announced by chemical makers worth around $185 billion that are under construction or planned. Such investments -- many backed by Federal government support -- are expected to boost capacity and export over the next several years.
Rebound in Construction
A recovery across housing and commercial construction -- major chemical end-markets -- has been another supporting factor for the chemical industry recovery. After being hit hard in the recession, the construction sector has bounced back on the back of healthy housing fundamentals.
Recent housing data has been fairly upbeat with U.S. housing starts scaling a four-month high in June, buoyed by a rise in both single-family and multi-family construction. Per the Commerce Department, housing starts climbed 8.3% to a seasonally adjusted annualized rate of 1.22 million units in June, the highest level since Feb 2017. Single-family starts rose 6.3% while construction of multi-family homes shot up 13.3%. Building permits, a proxy for future construction, also went up 7.4% for the month. These strong data paint an upbeat picture for U.S. homebuilding moving ahead.
The renewal of long-stalled construction projects and long-awaited access to credit from lending institutions has also helped invigorate the commercial construction sector. U.S. architecture firm billings continue to rise. The US Architecture Billings Index (ABI), an indicator that offers a glimpse into the future of U.S. non-residential construction spending activity, clocked 54.2 in June 2017 (a reading above 50 indicates an increase in billings), up from 53.0 in May. Moreover, the American Institute of Architects (AIA) expects non-residential construction spending to go up 3.8% in 2017 and 3.6% in 2018.
Positives such as an improving economy, steady buyer demand, low unemployment levels, low interest rates and positive consumer confidence raise optimism about the construction sector’s performance.
Healthy Automotive Demand
Chemical makers continue to see healthy demand from the automotive sector -- a major end-use market. The last two years have been exceptional for the auto sector. Sales in the U.S. saw record highs in both years, while sales in China and Europe also gained strength.
U.S. light vehicles (a key end-user market for chemicals) had a strong run in 2016, supported by an improving job market, rising personal income, improved consumer confidence, low fuel prices and attractive financing options. While recent sales trends suggest that the automotive industry has peaked, it is still in good health.
According to IHS Markit, global light vehicle sales are expected to increase 1.5% year over year to 93.5 million units in 2017. Moreover, IHS Markit sees U.S. light vehicle sales to reach 17.4 million units in 2017 -- a slight moderation from the 2016 level of 17.5 million units, but still looks poised for another strong year.
Low interest rates, favorable financing and cheap oil have also backed a recovery in the European auto market. The auto industry in Asian countries, especially China, is also expected to thrive over the next several years. This augurs well for chemical demand in this important end-market.
A Resurgent European Economy
The Eurozone economy has gained traction of late, as evident from recent upbeat economic data that suggest a recovery is steadily firming in the region. The European chemical industry has also swung back to life on the back of a rebounding Eurozone economy.
The Eurozone GDP rose 0.6% in the first quarter of 2017 (according to Eurostat data) on a quarter-over-quarter basis, the fastest pace since 2015 and also above expectations. The Eurozone also outstripped the U.S. when considering the annualized economic growth rate. While the Eurozone economy rose 2.3% on an annualized basis during the first quarter, the U.S. economy expanded 1.2%. The region’s recovery is backed by rising domestic demand, declining unemployment and strengthening business and consumer confidence.
While political risks may remain a drag, the Eurozone economy is poised for a strong 2017. The European Commission, in its spring 2017 forecast, said that it expects the Eurozone to grow 1.7% in 2017 (up from previous estimate of 1.6%), followed by 1.8% in 2018.
Chemical Bonding – M&A Binge Continues
Chemical makers remain actively focused on mergers and acquisitions to diversify and shore up growth. These companies are increasingly looking for cost synergy opportunities and enhanced operational scale through consolidations. The $130 billion mega-merger of Dow Chemical (NYSE: DOW – Free Report) and DuPont (NYSE: DD – Free Report) -- the biggest chemical deal ever -- is a huge testimony to these strategic moves.
Other major deals that have taken place in the chemical space in the recent past include ChemChina’s $43 billion acquisition of Syngenta (NYSE: SYT – Free Report), Albemarle Corp.’s (NYSE: ALB – Free Report) $6.2 billion buyout of Rockwood Holdings, Inc.,Merck KGaA's $17 billion acquisition of Sigma-Aldrich and the $66 billion proposed merger between Monsanto Company (NYSE: MON – Free Report) and Bayer AG.
Zacks Industry Rank
Within the Zacks Industry classification, health insurers are broadly grouped in the Medical sector (one of the 16 Zacks sectors).
We rank 265 industries into 16 Zacks sectors based on the earnings outlook and fundamental strength of the constituent companies in each industry. We put our X industries into two groups: the top half (industries with the best average Zacks Rank) and the bottom half (the industries with the worst average Zacks Rank).
Over the last 10 years, using a one-week rebalance, the top half beat the bottom half by more than twice as much. The Zacks Industry Rank is #177 (bottom 34%). The ranking is available on the Zacks Industry Rank page.
Strong Stocks that Should Be in the News
Many are little publicized and fly under the Wall Street radar. They're virtually unknown to the general public. Yet today's 220 Zacks Rank #1 "Strong Buys" were generated by the stock-picking system that has nearly tripled the market from 1988 through 2015. Its average gain has been a stellar +26% per year. See these high-potential stocks free >>.
Get the full Report on DOW - FREE
Get the full Report on DD - FREE
Get the full Report on SYT - FREE
Get the full Report on ALB - FREE
Get the full Report on MON - FREE
Follow us on Twitter: https://twitter.com/zacksresearch
Join us on Facebook: https://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Zacks Investment Research
800-767-3771 ext. 9339
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss.
This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit
https://www.zacks.com/performance for information about the performance numbers displayed in this press release.